In the BioHarmony Drug Report Database

"Preview" Icon

Palbociclib

Ibrance (palbociclib) is a small molecule pharmaceutical. Palbociclib was first approved as Ibrance on 2015-02-03. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against cyclin-dependent kinase 4 and cyclin-dependent kinase 6. Ibrance’s patents are valid until 2036-05-24 (FDA).

 

Trade Name

 

Ibrance
 

Common Name

 

palbociclib
 

ChEMBL ID

 

CHEMBL189963
 

Indication

 

breast neoplasms
 

Drug Class

 

Cyclin dependent kinase inhibitors

Image (chem structure or protein)

Palbociclib structure rendering